Market Place
Sourcing Support
Genmab to Hold 2024 R&D Update and ASH Data Review Meeting
11 Dec 2024 //
GLOBENEWSWIRE
Roche`s subQ Lunsumio matches IV version in lymphoma
10 Dec 2024 //
FIERCE PHARMA
Epcoritamab Monotherapy Shows High Response in Relapsed CLL Patients
08 Dec 2024 //
GLOBENEWSWIRE
Epcoritamab Combo Therapy Effective in Relapsed Follicular Lymphoma
07 Dec 2024 //
GLOBENEWSWIRE
Genmab buys 2nd antibody from Scancell in deal worth up to $630M
04 Dec 2024 //
FIERCE BIOTECH
Genmab to Present at Citi’s Global Healthcare Conference
25 Nov 2024 //
GLOBENEWSWIRE
Genmab open to more M&A if it makes `strategic sense
22 Nov 2024 //
FIERCE BIOTECH
Grant of Restricted Stock Units & Warrants to Employees in Genmab
21 Nov 2024 //
GLOBENEWSWIRE
Genmab axes 3 programs to focus on plumped-up pivotal pipeline
08 Nov 2024 //
FIERCE BIOTECH
Genmab Reports Financials for First Nine Months of 2024
06 Nov 2024 //
GLOBENEWSWIRE
Genmab Showcases Epcoritamab Development at ASH 2024
05 Nov 2024 //
GLOBENEWSWIRE
Genmab to Present at Jefferies London Healthcare Conference
05 Nov 2024 //
GLOBENEWSWIRE
Genmab to Present Epcoritamab-bysp Program at ASH 2024
05 Nov 2024 //
BUSINESSWIRE
Genmab Announces Net Sales of Darzalex for Third Quarter of 2024
15 Oct 2024 //
GLOBENEWSWIRE
Major Shareholder Announcement
04 Oct 2024 //
GLOBENEWSWIRE
Grant of Restricted Stock Units and Warrants to Employees in Genmab
26 Sep 2024 //
GLOBENEWSWIRE
Rinatabart Sesutecan Shows Promise In Ovarian And Endometrial Cancers
15 Sep 2024 //
GLOBENEWSWIRE
Genmab Announces Capital Increase From Warrant Exercise
10 Sep 2024 //
GLOBENEWSWIRE
Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
26 Aug 2024 //
GLOBENEWSWIRE
TEPKINLY Gets Second EC Approval For Relapsed Follicular Lymphoma
19 Aug 2024 //
GLOBENEWSWIRE
Genmab shuffles C-Suite on commercialization, manufacturing as portfolio grows
19 Aug 2024 //
FIERCE PHARMA
Genmab Announces Changes to its Executive Committee
16 Aug 2024 //
GLOBENEWSWIRE
Capital Increase in Genmab as a Result of Employee Warrant Exercise
13 Aug 2024 //
GLOBENEWSWIRE
Genmab A/S Reports Insider Transactions
13 Aug 2024 //
GLOBENEWSWIRE
Genmab Updates 2024 Financial Guidance
08 Aug 2024 //
GLOBENEWSWIRE
Genmab Announces Financial Results for the First Half of 2024
08 Aug 2024 //
GLOBENEWSWIRE
BioNTech ends work on Genmab-partnered bispecific antibody acasunlimab
05 Aug 2024 //
FIERCE BIOTECH
Genmab Takes Full Control of Acasunlimab Development Program
03 Aug 2024 //
GLOBENEWSWIRE
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024
17 Jul 2024 //
GLOBENEWSWIRE
Epcoritamab gets Positive CHMP Opinion for Relapsed Follicular Lymphoma
28 Jun 2024 //
GLOBENEWSWIRE
Completion of Share Buy-back Program
27 Jun 2024 //
GLOBENEWSWIRE
FDA grants accelerated approval to epcoritamab-bysp
27 Jun 2024 //
FDA
Genmab Us, Inc. Biologic Epcoritamab-Bysp Receives Approval in US
26 Jun 2024 //
FDA
EPKINLY Approved By FDA For Relapsed Follicular Lymphoma
26 Jun 2024 //
BUSINESSWIRE
Transactions in Connection with Share Buy-back Program
24 Jun 2024 //
GLOBENEWSWIRE
Capital Increase in Genmab as a Result of Employee Warrant Exercise
18 Jun 2024 //
GLOBENEWSWIRE
Transactions In Connection With Share Buy-back Program
17 Jun 2024 //
GLOBENEWSWIRE
Grant of Restricted Stock Units and Warrants to Employees in Genmab
12 Jun 2024 //
GLOBENEWSWIRE
Transactions with shares & linked securities in Genmab made by managerial
11 Jun 2024 //
GLOBENEWSWIRE
Transactions in Connection with Share Buy-back Program
10 Jun 2024 //
GLOBENEWSWIRE
Genmab: Fireside Chat At Goldman Sachs Healthcare Conference
05 Jun 2024 //
GLOBENEWSWIRE
Transactions in Connection with Share Buy-back Program
03 Jun 2024 //
GLOBENEWSWIRE
Tisotumab Vedotin Shows Activity In Recurrent/Metastatic HNSCC
03 Jun 2024 //
GLOBENEWSWIRE
Tisotumab Vedotin Active In Recurrent/Metastatic HNSCC Patients
03 Jun 2024 //
BUSINESSWIRE
Epcoritamab Combo Shows 95% ORR In Untreated Follicular Lymphoma
02 Jun 2024 //
GLOBENEWSWIRE
Acasunlimab Plus Pembro Shows Activity In Pretreated Metastatic NSCLC
01 Jun 2024 //
GLOBENEWSWIRE
Transactions in Connection with Share Buy-back Program
27 May 2024 //
GLOBENEWSWIRE
Genmab Various Patient Data: To Be Presented At Asco 2024
23 May 2024 //
GLOBENEWSWIRE
Transactions in Connection with Share Buy-back Program
21 May 2024 //
GLOBENEWSWIRE
Genmab Completes Acquisition of ProfoundBio
21 May 2024 //
GLOBENEWSWIRE
Genmab To Present Epcoritamab Data Across B-Cell Malignancies At EHA 2024
14 May 2024 //
GLOBENEWSWIRE
Transactions in Connection with Share Buy-back Program
13 May 2024 //
GLOBENEWSWIRE
Capital Increase in Genmab as a Result of Employee Warrant Exercise
06 May 2024 //
GLOBENEWSWIRE
Transactions in Connection with Share Buy-back Program
06 May 2024 //
GLOBENEWSWIRE
Genmab Announces Financial Results for the First Quarter of 2024
02 May 2024 //
GLOBENEWSWIRE
Transactions in Connection with Share Buy-back Program Genmab
29 Apr 2024 //
GLOBENEWSWIRE
TIVDAK® Approved by FDA for Recurrent/Metastatic Cervical Cancer
29 Apr 2024 //
GLOBENEWSWIRE
Transactions in Connection with Share Buy-back Program Genmab
22 Apr 2024 //
GLOBENEWSWIRE
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024
16 Apr 2024 //
GLOBENEWSWIRE
Genmab Share Buyback Program Transactions
15 Apr 2024 //
GLOBENEWSWIRE
